Endogenous opioids and liver disease

References

• Gutstein HB, Akil H. Opioid analgesics. Goodman & Gilman's the pharmacological basis of therapeutics10th ed, JG Hardman, LE Limird. McGraw-Hill, New York 2001; 569–619
   Google Scholar
• Musto DF. Opium, cocaine and marijuana in American history. Sci Am 1991; 265: 40–7
   PubMed Web of Science ®Google Scholar
• Luderitz B. Historical development of antiarrhythmic drug therapy. History of the disorders of cardiac rhythm. Futura Publishing Company, New York 1995; 83–106
   Google Scholar
• Robinson R. The structural relations of natural products. Oxford University Press, Oxford 1955
   Google Scholar
• Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996; 48: 567–92
   PubMed Web of Science ®Google Scholar
• Stefano GB, Hartman A, Bilfinger TV, Magazine HI, Liu Y, Casares F, et al. Presence of the mu3 opiate receptor in endothelial cells. Coupling to nitric oxide production and vasodilation. J Biol Chem 1995; 270: 30290–3
   PubMed Web of Science ®Google Scholar
• Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975; 258: 577–80
   PubMed Web of Science ®Google Scholar
• Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood L. Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci USA 1979; 76: 6666–70
   PubMed Web of Science ®Google Scholar
• Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997; 386: 499–502
   PubMed Web of Science ®Google Scholar
• Weitz CJ, Faull KF, Goldstein A. Synthesis of the skeleton of the morphine molecule by mammalian liver. Nature 1987; 330: 674–7
   PubMed Web of Science ®Google Scholar
• Stefano GB, Goumon Y, Casares F, Cadet P, Fricchione GL, Rialas C, et al. Endogenous morphine. Trends Neurosci 2000; 23: 436–42
   PubMed Web of Science ®Google Scholar
• Standifer KM, Pasternak GW. G proteins and opioid receptor-mediated signalling. Cell Signal 1997; 9: 237–48
   PubMed Web of Science ®Google Scholar
• Smythe CM, Gilmore JP. The effect of morphine on hepatic blood flow in the normal anesthetized dog. J Pharmacol Exp Ther 1995; 114: 221–4
   Google Scholar
• Roberts SM, Skoulis NP, James RC. A centrally-mediated effect of morphine to diminish hepatocellular glutathione. Biochem Pharmacol 1987; 36: 3001–5
   PubMed Web of Science ®Google Scholar
• James RC, Wessinger WD, Roberts SM, Millner GC, Paule MG. Centrally mediated opioid induced depression of hepatic glutathione: effects of intracerebroventricular administration of mu, kappa, sigma and delta agonists. Toxicology 1988; 51: 267–79
   PubMed Web of Science ®Google Scholar
• Wittert G, Hope P, Pyle D. Tissue distribution of opioid receptor gene expression in the rat. Biochem Biophys Res Commun 1996; 218: 877–81
   PubMed Web of Science ®Google Scholar
• Jaume M, Jacquet S, Cavailles P, Mace G, Stephan L, Blanpied C, et al. Opioid receptor blockade reduces Fas-induced hepatitis in mice. Hepatology 2004; 40: 1136–43
   PubMedGoogle Scholar
• Dobrenis K, Makman MH, Stefano GB. Occurrence of the opiate alkaloid-selective mu3 receptor in mammalian microglia, astrocytes and Kupffer cells. Brain Res 1995; 24: 239–48
   Google Scholar
• Ebrahimkhani, MR, Kiani, S, Kendall, T, Shariftabrizi, A, Tavangar, SM, Payabvash, S, et al. Naltrexone, an opioid antagonist, attenuates liver fibrosis in bile duct ligated rats. (submitted to Gut).
   Google Scholar
• Bergasa NV, Sabol SL, Young WS 3rd, Kleiner DE, Jones EA. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995; 268: G346–G54
   Google Scholar
• Bergasa NV, Liau S, Homel P, Ghali V. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 2002; 22: 107–13
   PubMedGoogle Scholar
• Thune A, Jivegard L, Pollard H, Moreau J, Schwartz JC, Svanvik J. Location of enkephalinase and functional effects of [Leu5]enkephalin and inhibition of enkephalinase in the feline main pancreatic and bile duct sphincters. Clin Sci (London) 1992; 82: 169–73
   PubMedGoogle Scholar
• Bergasa NV, Zhou J, Ravi J, Shi Q. The opioid peptide analog D-Ala2-Met-enkephalinamide decreases bile flow by a central mechanism. Peptides 1999; 20: 979–86
   PubMedGoogle Scholar
• May B, Helmstaedt D. Liver disease in drug addicts: clinical course-toxicological and clinical pharmacological aspects. Int J Clin Pharmacol Biopharm 1975; 12: 50–6
   PubMedGoogle Scholar
• de Araujo MS, Gerard F, Chossegros P, Porto LC, Barlet P, Grimaud JA. Vascular hepatotoxicity related to heroin addiction Virchows Arch A Pathol Anat Histopathol 1990; 417: 497–503
   PubMedGoogle Scholar
• Mani AR, Babaie A, Dehpour AR. Naltrexone is protective against liver damage induced by biliary obstruction. Toxicology 2001; 164: 131
   Google Scholar
• Gaskari SA, Mani AR, Ejtemaei-Mehr S, Namiranian K, Homayoun H, Ahmadi H. Do endogenous opioids contribute to the bradycardia of rats with obstructive cholestasis?. Fundam Clin Pharmacol 2002; 16: 273–9
   PubMedGoogle Scholar
• Ghaffari K, Savadkuhi ST, Honar H, Riazi K, Shafaroodi H, Moezi L. Obstructive cholestasis alters intestinal transit in mice: role of opioid system. Life Sci 2004; 76: 397–406
   Google Scholar
• Ebrahimkhani MR, Payabvash S, Mani AR, Shariftabrizi S, Kiani S, Pasalar P. Cholestasis and systemic oxidative stress: Roles for endogenous opioids. J Hepatol 2004; 40(Suppl 1)91
   Google Scholar
• Campbell SJ, Hughes PM, Iredale JP, Wilcockson DC, Waters S, Docagne F. CINC-1 is an acute-phase protein induced by focal brain injury causing leukocyte mobilization and liver injury. FASEB J 2003; 17: 1168–70
   PubMed Web of Science ®Google Scholar
• Svegliati-Baroni G, de Minitics S, Marzioni M, Saccomanno S, Benedetti A. Opioid receptors are differentially expressed during the process of hepatic stellate cell activation and modulate their proliferation and the development of liver fibrosis: An in vitro and in vivo study. Hepatology 2004; 40(Suppl 1)611A
   Google Scholar
• Li Y, Zhang T, Douglas SD, Lai JP, Xiao WD, Pleasure DE, et al. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 2003; 163: 1167–75
   PubMed Web of Science ®Google Scholar
• Thornton JR, Losowsky MS. Plasma methionine enkephalin concentration and prognosis in primary biliary cirrhosis. Br Med J 1988; 297: 1241–2
   PubMedGoogle Scholar
• Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. Br Med J 1988; 297: 1501–4
   PubMedGoogle Scholar
• Thornton JR, Losowsky MS. Methionine enkephalin is increased in plasma in acute liver disease and is present in bile and urine. J Hepatol 1989; 8: 53–9
   PubMedGoogle Scholar
• Thornton JR, Losowsky MS. Plasma leucine enkephalin is increased in liver disease. Gut 1989; 30: 1392–5
   PubMedGoogle Scholar
• Bergasa NV, Rothman RB, Vergalla J, Xu H, Swain MG, Jones EA. Central mu-opioid receptors are down-regulated in a rat model of cholestasis. J Hepatol 1992; 15: 220–4
   PubMedGoogle Scholar
• Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones EA. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992; 103: 630–5
   PubMed Web of Science ®Google Scholar
• Bergasa NV, Alling DW, Vergalla J, Jones EA. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 1994; 20: 85–90
   PubMedGoogle Scholar
• Ghafourifar P, Dehpour AR, Akbarloo N. Inhibition by L-NA, a nitric oxide synthase inhibitor of naloxone-precipitated withdrawal signs in a mouse model of cholestasis. Life Sci 1997; 60: 265–70
   Google Scholar
• Dehpour AR, Akbarloo N, Ghafourifar P. Endogenous nitric oxide modulates naloxone-precipitated withdrawal signs in a mouse model with acute cholestasis. Behav Pharmacol 1998; 9: 77–80
   PubMedGoogle Scholar
• Dehpour AR, Mani AR, Amanlou M, Nahavandi A, Amanpour S, Bahadori M. Naloxone is protective against indomethacin-induced gastric damage in cholestatic rats. J Gastroenterol 1999; 34: 178–81
   PubMedGoogle Scholar
• Dehpour AR, Rastegar H, Jorjani M, Roushanzamir F, Joharchi K, Ahmadiani A. Subsensitivity to opioids is receptor-specific in isolated guinea pig ileum and mouse vas deferens after obstructive cholestasis. J Pharmacol Exp Ther 2000; 293: 946–51
   PubMedGoogle Scholar
• Dehpour AR, Sadeghipour HR, Nowroozi A, Akbarloo N. The effect of the serotonergic system on opioid withdrawal-like syndrome in a mouse model of cholestasis. Hum Psychopharmacol 2000; 15: 423–8
   PubMedGoogle Scholar
• Dehpour AR, Samini M, Rastegar H, Ardeshiri AJ, Roushanzamir F, Jorjani M, et al. Effect of NMDA receptor antagonist on naloxone-precipitated withdrawal signs in cholestatic mice. Hum Psychopharmacol 2000; 15: 213–8
   PubMedGoogle Scholar
• Dehpour AR, Samini M, Arad MA, Namiranian K. Clonidine attenuates naloxone-induced opioid-withdrawal syndrome in cholestatic mice. Pharmacol Toxicol 2001; 89: 129–32
   PubMedGoogle Scholar
• Namiranian K, Samini M, Mehr SE, Gaskari SA, Rastegar H, Homayoun H, et al. Mesenteric vascular bed responsiveness in bile duct-ligated rats: roles of opioid and nitric oxide systems. Eur J Pharmacol 2001; 423: 185–93
   PubMedGoogle Scholar
• Nahavandi A, Mani AR, Homayounfar H, Akbari MR, Dehpour AR. The role of the interaction between endogenous opioids and nitric oxide in the pathophysiology of ethanol-induced gastric damage in cholestatic rats. Fundam Clin Pharmacol 2001; 15: 181–7
   PubMedGoogle Scholar
• Rastegar H, Homayoun H, Afifi M, Rezayat M, Dehpour AR. Modulation of cholestasis-induced antinociception by CCK receptor agonists and antagonists. Eur Neuropsychopharmacol 2002; 12: 111–8
   PubMedGoogle Scholar
• Demehri S, Namiranian K, Mehr SE, Rastegar H, Shariftabrizi A, Gaskari SA, et al. Alpha-2-adrenoceptor hyporesponsiveness in isolated tissues of cholestatic animals: involvement of opioid and nitric oxide systems. Life Sci 2003; 73: 209–20
   PubMedGoogle Scholar
• Demehri S, Samini M, Namiranian K, Rastegar H, Mehr SE, Homayoun H, et al. Alpha 2-adrenoceptor and NO mediate the opioid subsensitivity in isolated tissues of cholestatic animals. Auton Autacoid Pharmacol 2003; 23: 201–7
   PubMedGoogle Scholar
• Schoenfield LJ, Sjovall J, Perman E. Bile acids on the skin of patients with pruritic hepatobiliary disease. Nature 1967; 213: 93–4
   Web of Science ®Google Scholar
• Varadi DP. Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin. Arch Dermatol 1974; 109: 678–81
   PubMedGoogle Scholar
• Ghent CN, Bloomer JR. Itch in liver disease: facts and speculations. Yale J Biol Med 1979; 52: 77–82
   PubMed Web of Science ®Google Scholar
• Duffy BL. Itching as a side-effect of epidural morphine. Anaesthesia 1981; 36: 67
   PubMed Web of Science ®Google Scholar
• Thomas DA, Williams GM, Iwata K, Kenshalo DR, Jr, Dubner R. Effects of central administration of opioids on facial scratching in monkeys. Brain Res 1992; 585: 315–7
   PubMedGoogle Scholar
• Bergasa NV, Thomas DA, Vergalla J, Turner ML, Jones EA. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 1993; 53: 1253–7
   PubMedGoogle Scholar
• Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979; 115: 1366–7
   PubMedGoogle Scholar
• Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102: 544–9
   PubMed Web of Science ®Google Scholar
• Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995; 123: 161–7
   PubMed Web of Science ®Google Scholar
• Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998; 27: 679–84
   PubMed Web of Science ®Google Scholar
• Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999; 41: 431–4
   PubMed Web of Science ®Google Scholar
• Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113: 1264–9
   PubMed Web of Science ®Google Scholar
• Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37: 717–22
   PubMed Web of Science ®Google Scholar
• Jones EA, Dekker LR. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000; 118: 431–2
   PubMed Web of Science ®Google Scholar
• Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. Q J Med 2002; 95: 547–52
   Google Scholar
• McRae CA, Prince MI, Hudson M, Day CP, James OF, Jones DE. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003; 125: 591–6
   PubMed Web of Science ®Google Scholar
• Mitchell JE. Naltrexone and hepatotoxicity. Lancet 1986; 1: 1215
   PubMed Web of Science ®Google Scholar
• Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996; 91: 1022–3
   PubMedGoogle Scholar
• Sax DS, Kornetsky C, Kim A. Lack of hepatotoxicity with naltrexone treatment. J Clin Pharmacol 1994; 34: 898–901
   PubMed Web of Science ®Google Scholar
• Bomzon A, Jacob G, Better OS. Jaundice and the kidney. The kidney in liver disease4th ed, M Epstein. Hanley & Belfus, Philadelphia 1996; 423–46
   Google Scholar
• Jacob G, Said O, Finberg J, Bomzon A. Peripheral vascular neuroeffector mechanisms in experimental cholestasis. Am J Physiol 1993; 265: G579–G86
   Google Scholar
• Pak JM, Lee SS. Vasoactive effects of bile salts in cirrhotic rats: in vivo and in vitro studies. Hepatology 1993; 18: 1175–81
   PubMedGoogle Scholar
• Inan M, Sayek I, Tel BC, Sahin-Erdemli I. Role of endotoxin and nitric oxide in the pathogenesis of renal failure in obstructive jaundice. Br J Surg 1997; 84: 943–7
   PubMedGoogle Scholar
• Cioffi WG, DeMeules JE, Kahng KU, Wait RB. Renal vascular reactivity in jaundice. Surgery 1986; 100: 356–62
   PubMed Web of Science ®Google Scholar
• Song E, Segal I, Hodkinson J, Kew MC. Sinus bradycardia in obstructive jaundice: correlation with total serum bile acid concentrations. S Afr Med J 1983; 64: 548–51
   PubMedGoogle Scholar
• Binah O, Bomzon A, Blendis LM, Mordohovich D, Better OS. Obstructive jaundice blunts myocardial contractile response to isoprenaline in the dog: a clue to the susceptibility of jaundiced patients to shock?. Clin Sci (London) 1985; 69: 647–53
   PubMed Web of Science ®Google Scholar
• Nahavandi A, Dehpour AR, Mani AR, Homayounfar H, Abdoli A, Abdolhoseini MR. The role of nitric oxide in bradycardia of rats with obstructive cholestasis. Eur J Pharmacol 2001; 411: 135–41
   PubMedGoogle Scholar
• Mani AR, Nahavandi A, Moosavi M, Safarinejad R, Dehpour AR. Dual nitric oxide mechanisms of cholestasis-induced bradycardia in the rat. Clin Exp Pharmacol Physiol 2002; 29: 905–8
   PubMedGoogle Scholar
• Cadet P, Bilfinger TV, Fimiani C, Peter D, Stefano GB. Human vascular and cardiac endothelia express mu opiate receptor transcripts. Endothelium 2000; 7: 185–91
   PubMed Web of Science ®Google Scholar
• Sadeghipour H, Dehghani M, Dehpour AR. Role of opioid and nitric oxide systems in the nonadrenergic noncholinergic-mediated relaxation of corpus cavernosum in bile duct-ligated rats. Eur J Pharmacol 2003; 460: 201–7
   PubMedGoogle Scholar
• Moller S, Henriksen JH. Pathogenesis and pathophysiology of hepatorenal syndrome: is there scope for prevention?. Aliment Pharmacol Ther 2004; 20: 42–3
   PubMedGoogle Scholar
• Treiber G, Csepregi A, Malfertheiner P. The pathophysiology of portal hypertension. Dig Dis 2005; 23: 6–10
   PubMed Web of Science ®Google Scholar
• Thornton JR, Dean H, Losowsky MS. Is ascites caused by impaired hepatic inactivation of blood borne endogenous opioid peptides?. Gut 1988; 29: 1167–72
   PubMed Web of Science ®Google Scholar
• Horvath G. Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous mu-opioid receptor agonists. Pharmacol Ther 2000; 88: 437–63
   PubMedGoogle Scholar
• Leehey DJ, Gollapudi P, Deakin A, Reid RW. Naloxone increases water and electrolyte excretion after water loading in patients with cirrhosis and ascites. J Lab Clin Med 1991; 118: 484–91
   PubMedGoogle Scholar
• Lee SS, Hadengue A, Moreau R, Girod C, Jiron MI, Lebrec D. Naloxone does not alter haemodynamics in cirrhosis. Studies in humans and rats. J Hepatol 1987; 5: 149–53
   PubMedGoogle Scholar
• Bosch-Marce M, Jimenez W, Angeli P, Leivas A, Claria J, Graziotto A, et al. Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology 1995; 109: 217–23
   PubMed Web of Science ®Google Scholar
• Gines P, Jimenez W. Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis. J Hepatol 1996; 24: 506–12
   PubMedGoogle Scholar
• Moreau R, Cailmail S, Hamon G, Lebrec D. Renal and haemodynamic responses to a novel kappa opioid receptor agonist, niravoline (RU 51,599), in rats with cirrhosis. J Gastroenterol Hepatol 1996; 11: 857–63
   PubMed Web of Science ®Google Scholar
• Bosch-Marce M, Poo JL, Jimenez W, Bordas N, Leivas A, Morales-Ruiz M, et al. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention. J Pharmacol Exp Ther 1999; 289: 194–201
   PubMed Web of Science ®Google Scholar
• Gadano A, Moreau R, Pessione F, Trombino C, Giuily N, Sinnassamy P, et al. Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis. J Hepatol 2000; 32: 38–42
   PubMedGoogle Scholar
• Mercadante S, Arcuri E. Opioids and renal function. J Pain 2004; 5: 2–19
   PubMed Web of Science ®Google Scholar
• Jones EA, Skolnick P, Gammal SH, Basile AS, Mullen KD. The gamma-aminobutyric acid A (GABAA) receptor complex and hepatic encephalopathy. Some recent advances. Ann Intern Med 1989; 110: 532–46
   PubMedGoogle Scholar
• Basile AS, Jones EA. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997; 25: 1303–5
   PubMed Web of Science ®Google Scholar
• Butterworth RF. Hepatic encephalopathy: a neuropsychiatric disorder involving multiple neurotransmitter systems. Curr Opin Neurol 2000; 13: 721–7
   PubMed Web of Science ®Google Scholar
• Sasaki K, Fan LW, Tien LT, Ma T, Loh HH, Ho IK. The interaction of morphine and gamma-aminobutyric acid (GABA)ergic systems in anxiolytic behavior: using mu-opioid receptor knockout mice. Brain Res Bull 2002; 57: 689–94
   PubMedGoogle Scholar
• Bergasa NV, Rothman RB, Mukerjee E, Vergalla J, Jones EA. Up-regulation of central mu-opioid receptors in a model of hepatic encephalopathy: a potential mechanism for increased sensitivity to morphine in liver failure. Life Sci 2002; 70: 1701–8
   PubMed Web of Science ®Google Scholar
• Laidlaw J, Read AE, Sherlock S. Morphine tolerance in hepatic cirrhosis Gastroenterology 1961; 40: 389–96
   Google Scholar
• Yurdaydin C. The central opioid system in liver disease and its complications. Metab Brain Dis 2001; 16: 79–83
   PubMed Web of Science ®Google Scholar
• de Waele JP, Audet RM, Leong DK, Butterworth RF. Portacaval anastomosis induces region-selective alterations of the endogenous opioid system in the rat brain. Hepatology 1996; 24: 895–901
   PubMedGoogle Scholar
• Yurdaydin C, Karavelioglu D, Onaran O, Celik T, Yasa MH, Uzunalimoglu O. Opioid receptor ligands in human hepatic encephalopathy. J Hepatol 1998; 29: 796–801
   PubMedGoogle Scholar
• Ozsoylu S, Kocak N. Naloxone in hepatic encephalopathy. Am J Dis Child 1985; 139: 749–50
   PubMedGoogle Scholar
• Yurdaydin C, Li Y, Ha JH, Jones EA, Rothman R, Basile AS. Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid antagonists. J Pharmacol Exp Ther 1995; 273: 185–92
   PubMedGoogle Scholar
• Homayoun H, Sayyah M, Dehpour AR. The additive effect of opioids and nitric oxide in increasing pentylenetetrazole-induced seizure threshold in cholestatic mice. J Gastroenterol Hepatol 2002; 17: 96–101
   PubMedGoogle Scholar
• Swain MG, Vergalla J, Bergasa NV, Jones EA. Sympathetic nerves, but not the adrenal gland, contribute to elevated plasma levels of met-enkephalin in rats with acute cholestatic hepatitis. Regul Pept 1993; 46: 535–42
   PubMedGoogle Scholar
• Swain MG, MacArthur L, Vergalla J, Jones EA. Adrenal secretion of BAM-22P, a potent opioid peptide, is enhanced in rats with acute cholestasis. Am J Physiol 1994; 266: G201–5
   Google Scholar
• Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422–33
   PubMed Web of Science ®Google Scholar
• D'Amato R, Holaday JW. Multiple opioid receptors in endotoxic shock: evidence for delta involvement and mu-delta interactions in vivo. Proc Natl Acad Sci USA 1984; 81: 2898–901
   PubMedGoogle Scholar
• Napolitano L, Chernow B. Endorphins in circulatory shock. Crit Care Med 1988; 16: 566–7
   PubMedGoogle Scholar
• Goumon Y, Bouret S, Casares F, Zhu W, Beauvillain JC, Stefano GB. Lipopolysaccharide increases endogenous morphine levels in rat brain. Neurosci Lett 2000; 293: 135–8
   PubMed Web of Science ®Google Scholar
• Le Moine O, Soupison T, Sogni P, Marchant A, Moreau R, Hadengue A, et al. Plasma endotoxin and tumor necrosis factor-alpha in the hyperkinetic state of cirrhosis. J Hepatol 1995; 23: 391–5
   PubMedGoogle Scholar
• Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology 2000; 118: 937–44
   PubMed Web of Science ®Google Scholar
• Bigatello LM, Broitman SA, Fattori L, Di Paoli M, Pontello M, Bevilacqua G, et al. Endotoxemia, encephalopathy, and mortality in cirrhotic patients. Am J Gastroenterol 1987; 82: 11–15
   PubMed Web of Science ®Google Scholar